Corporate Investor

Updated:

Thuasne

Founded in 1847 as a silk ribbon manufacturer in Saint-Étienne, Thuasne pivoted into medical textiles in the early 20th century and has remained under the...

Thuasne logo

Thuasne

Founded in 1847 as a silk ribbon manufacturer in Saint-Étienne, Thuasne pivoted into medical textiles in the early 20th century and has remained under the direct control of the founding family for six generations. Elizabeth Ducottet, the fifth-generation leader, serves as Chairman and CEO alongside her daughter Delphine Hanton, who was appointed CEO in recent years, while her son Matthieu Ducottet directs innovation strategy. The wealth originates entirely from industrial manufacturing of orthopedic braces, compression stockings, and homecare products — a business that has survived two world wars, deindustrialization pressures, and multiple healthcare reimbursement regime changes. The group's investment posture is that of an industrial corporate venture operator rather than a financial allocator. Manufacturing output from six owned production sites — three in Saint-Étienne, one in Bakersfield, California, and a Knit-Rite/Therafirm facility in Kansas City — generates the capital that Thuasne reinvests into adjacent health-tech ventures. The group targets medical device innovation, digital health monitoring tools for compression therapy patients, and orthopedic rehabilitation technologies. Unlike a typical family office that allocates to external funds, Thuasne's investment activity is inseparable from its operating business; the innovation pipeline feeds directly into its manufacturing and distribution network spanning 85 countries. The firm's US headquarters on Shepard Street in Bakersfield anchors its North American commercial and manufacturing presence. Thuasne operates through Holding Thuasne, the family entity that sits above the operating companies and manages reinvestment decisions. Elizabeth Ducottet's external roles — she co-presides over METI, the French mid-cap business association, and holds membership in the French Academy of Technologies — position the group at the intersection of French industrial policy and health-tech innovation. Delphine Hanton's recognition by the Women's Forum for the Economy & Society signals the family's deliberate cultivation of female leadership through a structured generational transition. The group also maintains Thuasne Lab, its philanthropic vehicle for health-related research support. What distinguishes Thuasne structurally is its identity as a pure industrial company that performs its own corporate venture function without establishing a separate investment arm. There is no external LP capital, no fund structure, and no co-investment syndicate — only operating profits from a 177-year-old manufacturing business redeployed into the same sector the family knows from the factory floor. This self-funded, sector-concentrated model is rare among European industrial families, most of whom diversified into financial portfolios generations ago.

General information

Firm type

Corporate Investor

Year founded

1847

AUM

Undisclosed

Location

Region

North America

Country

France

City

Saint-Étienne

Corporate office

Saint-Étienne, France

Additional offices

Bakersfield, CA, United States · Kansas City, KS, United States

Principals

Elizabeth Ducottet

Chairman and CEO

Delphine Hanton

CEO

Matthieu Ducottet

Innovation Director

Sector focus

Digital HealthHealthcare ServicesMedical Devices

Frequently asked questions

Who makes the investment decisions at Thuasne?

Investment decisions appear to be made through Holding Thuasne, the family holding entity, with direct oversight from Elizabeth Ducottet as Chairman and CEO and Delphine Hanton as CEO of the group. The group does not operate a separate family office with an independent CIO — the industrial leadership team and the investment function are the same people. Public record indicates the sixth generation, including Matthieu Ducottet as Innovation Director, is deeply involved in capital allocation toward new technologies.

How does Thuasne source opportunities given it has no fund structure?

Thuasne sources through its industrial supply chain and clinical research networks rather than through traditional private-market channels. As a manufacturer supplying orthopedics and compression devices to 85 countries, the group identifies complementary technologies through its relationships with hospitals, rehabilitation centers, and materials science researchers. Elizabeth Ducottet's leadership roles in METI and the French Academy of Technologies provide additional visibility into French health-tech innovation.

Where does the underlying wealth come from?

The wealth is entirely industrial — generated by manufacturing medical compression textiles, orthopedic braces, and homecare devices since 1847. The group started as a silk ribbon manufacturer in Saint-Étienne and transformed into a medical supplier. Sixth-generation family control means no liquidity events, no external shareholders, and no financial-engineering wealth creation events have occurred.

Does Thuasne maintain philanthropic structures, and how are they separated?

Thuasne Lab serves as the group's philanthropic vehicle, focused on health-related research support. It is structurally separate from Holding Thuasne and the operating companies, though the family's dual leadership in both commercial and philanthropic activities means some strategic alignment is inevitable given the sector focus.

Is Thuasne structured as a family office or does it operate as a pure industrial company?

Thuasne is not a family office in the traditional sense — it is a pure industrial company that performs its own corporate venture function. There is no separate investment entity with a diversified portfolio of external funds or direct investments in unrelated sectors. The group reinvests operating profits exclusively into medical technology and adjacent health ventures, making it a corporate investor that happens to be family-controlled.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on asset managers?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Saint-Étienne Corporate Investor profiles